State Medicaid Spending on Sovaldi: Wide Variation in Spending and Utilization in 2014

By Janet Weiner, PhD, MPH September 25, 2015

These results — together with Medicaid budgetary constraints, high drug costs, and the increasing availability of other expensive, new medications — underscore the need to identify effective strategies to guide policy and reimbursement in order to ensure parity and appropriateness in the use of sofosbuvir among the Medicaid population and other high-need populations, such as prisoners and low-income patients who are not eligible for Medicaid, especially in states that did not expand Medicaid coverage.